The AbCellera Biologics story

What drives the business

• AbCellera combines antibody discovery partnerships with an internal drug pipeline, receiving technology access and research fees upfront while expecting most partnership economics to come from later milestones and royalties.
• Its Jazz Pharmaceuticals collaboration covers T-cell engagers for gastrointestinal cancers and other solid tumors, with $84 million in total upfront payments and eligibility for up to $792 million per program in option fees and milestone payments, plus royalties.
• The July 2026 Vertex Pharmaceuticals agreement covers multispecific T-cell engagers for autoimmune diseases and other conditions, with $28 million in upfront payments, Vertex funding all research and development costs, and potential milestones and royalties.
• ABCL635 is being developed as a non-hormonal, long-acting injection for hot flashes associated with menopause, and its Phase 2 study showed a mean placebo-adjusted reduction of 5.3 moderate and severe events per day at week 4.
• The December 2025 Bruker patent settlement adds another source of licensing revenue through $36 million upfront and future royalties on worldwide sales of Beacon Optofluidic platform products through the life of the licensed patents.

What the price assumes

The reverse DCF cannot measure the growth implied by the price because free cash flow and operating earnings are both negative, leaving the valuation dependent on future profits rather than an established positive cash flow base.

At $13.01 per share and a $4.0 billion market value, AbCellera trades at 60.3x sales, compared with the TenQ sales valuation check's bar of under 2.5x.

Revenue grew 101.3% over the last twelve months to $66 million, but annual revenue growth over the last three years was -46.3% and free cash flow over the last twelve months was -$120 million.

What could change the story

• The FDA may require additional studies before allowing Phase 3 trials based on the Canadian clinical results, and favorable early results do not establish later-stage safety, efficacy, or approval.
• Partner-led programs believed to be progressing fell to 35 at June 2026 from 44 at December 2025, underscoring dependence on partners whose development priorities and milestone timing AbCellera does not control.
• Research and development expenses rose to $46.0 million in the quarter to June 2026 from $39.2 million in the prior year quarter, while TenQ's Quality checks passed 0 of 6 amid losses and negative operating cash flow.
• Management described liquidity as sufficient for at least the next 36 months, but that assessment includes government contributions and depends on revenue growth, expansion costs, and partner milestone payments.
• In August 2026, AbCellera announced an offering expected to raise approximately $200.0 million in gross proceeds for its pipeline and other corporate purposes, with common shares and pre-funded warrants introducing dilution.

What to watch next

• The August 2026 ABCL635 results fulfilled the earnings release's planned readout, making regulatory feedback and the path toward Phase 3 the next clinical developments to follow.
• AbCellera expected top-line results from the Phase 1 study of ABCL575 in the fourth quarter of 2026 after completing dosing.
• Later releases can show whether partner-led programs stabilize from 35 and whether the 12 clinical molecules in which AbCellera held downstream stakes continue progressing.
• Research spending, cash use, receipt of collaboration payments, and confirmation of the announced offering's completion will clarify how the company is funding its clinical plans.

Sources

• AbCellera Biologics's earnings release, filed with the SEC
• Its latest 10-Q or 10-K, for the risk factors
• The ABCL stock report, for every figure and check